| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 2.369 | 15.833 | 21.059 | 19.133 | 17.536 | 16.104 | 16.795 | 22.595 |
| Total Income - EUR | - | - | 2.369 | 15.835 | 21.062 | 19.714 | 17.538 | 16.105 | 16.802 | 22.613 |
| Total Expenses - EUR | - | - | 1.794 | 16.188 | 19.143 | 18.881 | 17.612 | 16.755 | 16.566 | 20.637 |
| Gross Profit/Loss - EUR | - | - | 575 | -353 | 1.918 | 833 | -74 | -650 | 235 | 1.976 |
| Net Profit/Loss - EUR | - | - | 504 | -511 | 1.708 | 657 | -229 | -811 | 67 | 1.768 |
| Employees | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Semperviva Biohealth Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 104 | 4 | 0 | 0 | 0 | 0 | 6 | 0 |
| Current Assets | - | - | 9.762 | 9.529 | 10.863 | 11.565 | 10.116 | 8.964 | 10.407 | 14.098 |
| Inventories | - | - | 9.009 | 9.091 | 9.372 | 10.995 | 8.959 | 8.274 | 8.426 | 10.500 |
| Receivables | - | - | 18 | 30 | 0 | 151 | 291 | 359 | 186 | 240 |
| Cash | - | - | 736 | 409 | 1.490 | 419 | 867 | 331 | 1.794 | 3.357 |
| Shareholders Funds | - | - | 548 | 26 | 1.733 | 2.358 | 2.077 | 1.272 | 1.336 | 3.096 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 9.319 | 9.507 | 9.129 | 9.207 | 8.039 | 7.692 | 9.077 | 11.002 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4719 - 4719" | |||||||||
| CAEN Financial Year |
4719
|
|||||||||
Comments - Semperviva Biohealth Srl